Genetic Technologies Ltd (GENE) - Total Assets
Based on the latest financial reports, Genetic Technologies Ltd (GENE) holds total assets worth $6.19 Million USD as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Genetic Technologies Ltd for net asset value and shareholders' equity analysis.
Genetic Technologies Ltd - Total Assets Trend (2000–2024)
This chart illustrates how Genetic Technologies Ltd's total assets have evolved over time, based on quarterly financial data.
Genetic Technologies Ltd - Asset Composition Analysis
Current Asset Composition (June 2024)
Genetic Technologies Ltd's total assets of $6.19 Million consist of 59.7% current assets and 40.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.5% |
| Accounts Receivable | $2.13 Million | 34.4% |
| Inventory | $206.47K | 3.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $360.06K | 5.8% |
| Goodwill | $1.78 Million | 28.9% |
Asset Composition Trend (2000–2024)
This chart illustrates how Genetic Technologies Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GENE stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genetic Technologies Ltd's current assets represent 59.7% of total assets in 2024, a decrease from 61.1% in 2000.
- Cash Position: Cash and equivalents constituted 16.5% of total assets in 2024, up from 13.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 34.4% of total assets.
Genetic Technologies Ltd Competitors by Total Assets
Key competitors of Genetic Technologies Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.22 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.43 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$1.33 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Genetic Technologies Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.88 | 3.17 | 2.14 |
| Quick Ratio | 0.83 | 3.07 | 2.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-500.09K | $7.19 Million | $1.70 Million |
Genetic Technologies Ltd - Advanced Valuation Insights
This section examines the relationship between Genetic Technologies Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.29 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | -58.4% |
| Total Assets | $6.19 Million |
| Market Capitalization | $3.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genetic Technologies Ltd's assets below their book value (0.60x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genetic Technologies Ltd's assets decreased by 58.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genetic Technologies Ltd (2000–2024)
The table below shows the annual total assets of Genetic Technologies Ltd from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $6.19 Million | -58.36% |
| 2023-06-30 | $14.86 Million | -28.58% |
| 2022-06-30 | $20.80 Million | -9.45% |
| 2021-06-30 | $22.97 Million | +46.94% |
| 2020-06-30 | $15.63 Million | +378.80% |
| 2019-06-30 | $3.27 Million | -47.05% |
| 2018-06-30 | $6.17 Million | -49.08% |
| 2017-06-30 | $12.11 Million | -8.89% |
| 2016-06-30 | $13.29 Million | -35.86% |
| 2015-06-30 | $20.72 Million | +207.91% |
| 2014-06-30 | $6.73 Million | -19.12% |
| 2013-06-30 | $8.32 Million | -49.40% |
| 2012-06-30 | $16.44 Million | +84.28% |
| 2011-06-30 | $8.92 Million | +7.76% |
| 2010-06-30 | $8.28 Million | -62.83% |
| 2009-06-30 | $22.28 Million | -7.75% |
| 2008-06-30 | $24.15 Million | +15.25% |
| 2007-06-30 | $20.95 Million | -6.64% |
| 2006-06-30 | $22.44 Million | -23.31% |
| 2005-06-30 | $29.26 Million | +30.71% |
| 2004-06-30 | $22.39 Million | -25.97% |
| 2003-06-30 | $30.25 Million | -8.35% |
| 2002-06-30 | $33.00 Million | -16.84% |
| 2001-06-30 | $39.69 Million | +348.58% |
| 2000-06-30 | $8.85 Million | -- |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more